Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ameluz PDT for Actinic Keratosis
NCT01966120Phase 3Completed
- Sponsor
- Biofrontera
- Start
- Oct 2013
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in actinic keratosis (AK) comparing Ameluz + PDT with Placebo + PDT (2 arms). Primary endpoint: Overall Patient Complete Response 12 Weeks After the Last Photodynamic Therapy (PDT). Started Oct 2013; status: completed.
02
Drugs
aminolevulinic acid 10% gel
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT01966120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01966120.